Biotransformation of deramciclane in primary hepatocytes of rat, mouse, rabbit, dog, and human

K. Monostory, Krisztina Kohalmy, K. Ludányi, Gábor Czira, S. Holly, L. Vereczkey, Iván Ürmös, I. Klebovich, L. Kóbori

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The metabolic fate of deramciclane [(1R,2S,4R)-(-)-2-phenyl-2-(2′- dimethylamino-ethoxy)-1,7,7-trimethyl-bicyclo[2.2.1]heptane], a new anxiolytic drug candidate, has been determined in rat, mouse, rabbit, dog, and human hepatocytes. Rat and rabbit cells were the most active, whereas the rate of metabolism was quite slow in human hepatocytes. During biotransformation, deramciclane underwent side chain modification and oxidation at several positions of the molecule. The side chain modification led to the formation of N-desmethyl deramciclane and phenylborneol. The oxidation of deramciclane resulted in several hydroxy-, carboxy-, and N-oxide derivatives. The hydroxylation took place at primary or secondary carbons of the camphor ring as well as at the side chain; furthermore, dihydroxylated derivatives were also found. The side chain-modified metabolites were also oxidized to hydroxy- or carboxy-derivatives. Conjugation of phase I metabolites, as a route of elimination, was also observed in rat, rabbit, and dog hepatocytes. Although there were some species differences in biotransformation of deramciclane, it was concluded that phase I metabolism in human liver cells seemed to be similar to the metabolism in the hepatocytes isolated from rat. With careful approach, the rat model may be considered to be predictive for human metabolism of deramciclane.

Original languageEnglish
Pages (from-to)1708-1716
Number of pages9
JournalDrug Metabolism and Disposition
Volume33
Issue number11
DOIs
Publication statusPublished - Nov 2005

Fingerprint

Biotransformation
Rats
Hepatocytes
Dogs
Rabbits
Metabolism
Metabolites
Derivatives
Camphor
Oxidation
Hydroxylation
Anti-Anxiety Agents
Liver
Oxides
deramciclane
Carbon
Molecules
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

Biotransformation of deramciclane in primary hepatocytes of rat, mouse, rabbit, dog, and human. / Monostory, K.; Kohalmy, Krisztina; Ludányi, K.; Czira, Gábor; Holly, S.; Vereczkey, L.; Ürmös, Iván; Klebovich, I.; Kóbori, L.

In: Drug Metabolism and Disposition, Vol. 33, No. 11, 11.2005, p. 1708-1716.

Research output: Contribution to journalArticle

@article{7ea27d1438544f328b111b7249b98401,
title = "Biotransformation of deramciclane in primary hepatocytes of rat, mouse, rabbit, dog, and human",
abstract = "The metabolic fate of deramciclane [(1R,2S,4R)-(-)-2-phenyl-2-(2′- dimethylamino-ethoxy)-1,7,7-trimethyl-bicyclo[2.2.1]heptane], a new anxiolytic drug candidate, has been determined in rat, mouse, rabbit, dog, and human hepatocytes. Rat and rabbit cells were the most active, whereas the rate of metabolism was quite slow in human hepatocytes. During biotransformation, deramciclane underwent side chain modification and oxidation at several positions of the molecule. The side chain modification led to the formation of N-desmethyl deramciclane and phenylborneol. The oxidation of deramciclane resulted in several hydroxy-, carboxy-, and N-oxide derivatives. The hydroxylation took place at primary or secondary carbons of the camphor ring as well as at the side chain; furthermore, dihydroxylated derivatives were also found. The side chain-modified metabolites were also oxidized to hydroxy- or carboxy-derivatives. Conjugation of phase I metabolites, as a route of elimination, was also observed in rat, rabbit, and dog hepatocytes. Although there were some species differences in biotransformation of deramciclane, it was concluded that phase I metabolism in human liver cells seemed to be similar to the metabolism in the hepatocytes isolated from rat. With careful approach, the rat model may be considered to be predictive for human metabolism of deramciclane.",
author = "K. Monostory and Krisztina Kohalmy and K. Lud{\'a}nyi and G{\'a}bor Czira and S. Holly and L. Vereczkey and Iv{\'a}n {\"U}rm{\"o}s and I. Klebovich and L. K{\'o}bori",
year = "2005",
month = "11",
doi = "10.1124/dmd.105.003764",
language = "English",
volume = "33",
pages = "1708--1716",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "11",

}

TY - JOUR

T1 - Biotransformation of deramciclane in primary hepatocytes of rat, mouse, rabbit, dog, and human

AU - Monostory, K.

AU - Kohalmy, Krisztina

AU - Ludányi, K.

AU - Czira, Gábor

AU - Holly, S.

AU - Vereczkey, L.

AU - Ürmös, Iván

AU - Klebovich, I.

AU - Kóbori, L.

PY - 2005/11

Y1 - 2005/11

N2 - The metabolic fate of deramciclane [(1R,2S,4R)-(-)-2-phenyl-2-(2′- dimethylamino-ethoxy)-1,7,7-trimethyl-bicyclo[2.2.1]heptane], a new anxiolytic drug candidate, has been determined in rat, mouse, rabbit, dog, and human hepatocytes. Rat and rabbit cells were the most active, whereas the rate of metabolism was quite slow in human hepatocytes. During biotransformation, deramciclane underwent side chain modification and oxidation at several positions of the molecule. The side chain modification led to the formation of N-desmethyl deramciclane and phenylborneol. The oxidation of deramciclane resulted in several hydroxy-, carboxy-, and N-oxide derivatives. The hydroxylation took place at primary or secondary carbons of the camphor ring as well as at the side chain; furthermore, dihydroxylated derivatives were also found. The side chain-modified metabolites were also oxidized to hydroxy- or carboxy-derivatives. Conjugation of phase I metabolites, as a route of elimination, was also observed in rat, rabbit, and dog hepatocytes. Although there were some species differences in biotransformation of deramciclane, it was concluded that phase I metabolism in human liver cells seemed to be similar to the metabolism in the hepatocytes isolated from rat. With careful approach, the rat model may be considered to be predictive for human metabolism of deramciclane.

AB - The metabolic fate of deramciclane [(1R,2S,4R)-(-)-2-phenyl-2-(2′- dimethylamino-ethoxy)-1,7,7-trimethyl-bicyclo[2.2.1]heptane], a new anxiolytic drug candidate, has been determined in rat, mouse, rabbit, dog, and human hepatocytes. Rat and rabbit cells were the most active, whereas the rate of metabolism was quite slow in human hepatocytes. During biotransformation, deramciclane underwent side chain modification and oxidation at several positions of the molecule. The side chain modification led to the formation of N-desmethyl deramciclane and phenylborneol. The oxidation of deramciclane resulted in several hydroxy-, carboxy-, and N-oxide derivatives. The hydroxylation took place at primary or secondary carbons of the camphor ring as well as at the side chain; furthermore, dihydroxylated derivatives were also found. The side chain-modified metabolites were also oxidized to hydroxy- or carboxy-derivatives. Conjugation of phase I metabolites, as a route of elimination, was also observed in rat, rabbit, and dog hepatocytes. Although there were some species differences in biotransformation of deramciclane, it was concluded that phase I metabolism in human liver cells seemed to be similar to the metabolism in the hepatocytes isolated from rat. With careful approach, the rat model may be considered to be predictive for human metabolism of deramciclane.

UR - http://www.scopus.com/inward/record.url?scp=27544480571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27544480571&partnerID=8YFLogxK

U2 - 10.1124/dmd.105.003764

DO - 10.1124/dmd.105.003764

M3 - Article

C2 - 16118331

AN - SCOPUS:27544480571

VL - 33

SP - 1708

EP - 1716

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 11

ER -